“Compliance Debt”: What it is, and how it threatens Biotech Valuations

The clinical timeline is no longer the monopoly concern of the biotech sector. The newly imposed regulatory timeline, pushed by the BIOSECURE Act, makes it clear to the world that the United States has an agenda for the biotechnology industry: De-shoring is now just as critical as passing an FDA trial. These two hurdles are now intertwining to create “compliance debt”. Much like technical debt, compliance debt can accumulate quickly and come with severe consequences in the next 5-7 years.

The passing of the BIOSECURE Act in the NDAA FY 2026 signals a shift in the regulatory infrastructure of US biosecurity. Life sciences firms are now restricted from contracting with “Biotechnology Companies of Concern” (BCCs), particularly those in adversarial countries like China. This legislation offers a five-year grandfathering period for existing contracts, and its within this grandfathering period that we find the false sense of security fueling this compliance debt.

The mismatch is found in the development timelines. Drug development typically takes between 10 and 12 years from discovery to approval (DiMasi et al., 2016), which is double the length of the grandfathering period. This means that a company currently sitting in Phase I or II trials utilizing sequencing hardware, bioinformatics software, or any contract and development organization (CDMO) tied in a BCC parent network may be flagged as non-compliant before reaching the biologics license application (BLA) submission or commercialization stages.

There is tangible financial risk associated with these timeline misalignments. In mergers, acquisitions, and public offerings, a firm’s due diligence often extends beyond clinical data and intellectual property to include regulatory exposure and supply chain integrity. Both investors and acquirers have placed a growing emphasis on the auditability of an operation: they need verifiable assurance that critical inputs, from software to bench reagents, meet emerging biosecurity standards. Companies that fail this requirement may face discounted valuations or failed transactions (McKinsey & Company, 2023).

The Act itself is vague. The June memo from the Office of Management and Budget is expected to clear some of this haze, and hopefully by December (the official OMB BCC list drop) we will have a full, clear vision of the regulatory machine that this Act actually represents. What we do know now is that compliance can no longer be treated as a downstream, “check-the-box” function”. Instead, it should be a part of the conversation from the earliest stages of research and development. Proactive companies that audit their supply chains, diversify their vendors, and implement automated compliance verification infrastructure will be better positioned to navigate the regulatory landscape as it continues to evolve before our eyes.

— Evaristo at biogate